/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Team and project manager with more than 20 years’ experience of managing global biopharmaceutical development programs and leading cross-functional teams in both large pharma and small biotech companies. Solid experience of all phases of clinical drug development with focus on design of innovative and patient-focused paths to market and effective management of global, cross-functional teams.
Investigation of the effect of the angiotensin II type 2 receptor (AT2R) agonist C21 on plasma NT-proBNP, a diagnostic biomarker, in subjects hospitalised with COVID-19
Event: ESC Congress 2022
Topic: Biomarkers
Session: Cardiovascular aspects of COVID and long-COVID
ESC 365 is supported by
